Claims
- 1. A method for diagnosing a disease associated with oxidation of docosahexaenoic acid (DHA) containing lipids in a test subject, comprising:
determining the level of 2-(ω-carboxyethyl) pyrrole (CEP) adducts in a bodily fluid obtained from the test subject, wherein the presence of an elevated level of CEP adducts in the test subject's bodily fluid as compared to the level of CEP adducts found in a corresponding bodily fluid obtained from control subjects indicates that the test subject has a disease associated with oxidative damage to tissue comprising DHA containing lipids.
- 2. The method of claim 1 wherein the bodily fluid is whole blood, serum, or plasma.
- 3. The method of claim 1 wherein the disease is age-related macular degeneration (AMD).
- 4. The method of claim 1 wherein the disease is AMD and the level of CEP adducts in the bodily fluid are determined by contacting the bodily fluid with an anti-CEP antibody and assaying for the formation of an antigen-antibody complex between the anti-CEP antibody and a molecule in the bodily fluid.
- 5. The method of claim 1 wherein an antioxidant, a protease inhibitor, or both have been added to the bodily fluid following isolation of the bodily fluid from the test subject.
- 6. The method of claim 1 wherein the disease is AMD and wherein the levels of CEP adducts in the bodily fluid is compared to a predetermined value obtained by determining the level of CEP adducts in a corresponding bodily fluid obtained from healthy subjects.
- 7. The method of claim 1 wherein the disease is AMD and wherein the levels of CEP adducts are determined in a plurality of bodily fluids obtained at successive time intervals from the test subject.
- 8. The method of claim 1 wherein the disease is AMD and wherein the assay comprises determining the levels of CEP adducts in a bodily fluid obtained from the subject at a time prior to treatment with an anti-AMD drug and determining the levels of the CEP adducts in a corresponding bodily fluid obtained from the subject at a time following treatment with the anti-AMD drug.
- 9. The method of claim 4 wherein the antibody is a monoclonal antibody.
- 10. The method of claim 4 wherein the antibody has more than 100 fold greater affinity for a CEP adduct than a 2-(ω-carboxypropyl) pyrrole (CPP) adduct.
- 11. The method of claim 1 wherein the disease is atherosclerosis.
- 12. A method for characterizing a test subjects predisposition to developing age-related macular degeneration or atherosclerosis, comprising:
determining the level of CEP adducts in a bodily fluid obtained from the test subject, wherein the presence of an elevated level of CEP adducts in the test subject's bodily fluid as compared to the level of CEP adducts found in a corresponding bodily fluid obtained from control subjects indicates that the test subject has AMD or atherosclerosis or a predisposition to developing AMD or atherosclerosis.
- 13. The method of claim 12 wherein the bodily fluid is whole blood, serum, or plasma.
- 14. The method of claim 12 wherein the level of CEP adducts in the bodily fluid are determined by contacting the bodily fluid with an anti-CEP antibody and assaying for the formation of an antigen-antibody complex between said antibody and a molecule in the bodily fluid.
- 15. The method of claim 12 wherein an antioxidant, protease inhibitor, or both have been added to the bodily fluid following isolation after the bodily fluid from the test subject.
- 16. A method of identifying a subject who has or is at risk of developing a disease associated with oxidation of DHA-containing lipids, comprising
determining the level of anti-CEP antibodies in a bodily fluid obtained from the test subject, wherein the presence of an elevated level of anti-CEP antibodies in the test subject's bodily fluid as compared to the level of anti-CEP antibodies found in a corresponding bodily fluid obtained from control subjects indicates that the test subject has a disease associated with oxidation of DHA-containing lipids.
- 17. The method of claim 16 wherein the subject is suspected of having AMD or a predisposition to developing AMD.
- 18. The method of claim 16 wherein the subject is suspected of having atherosclerosis or a predisposition to developing atherosclerosis.
- 19. A diagnostic kit for diagnosing diseases which involve oxidation of DHA, comprising:
an antibody reactive with a CEP adduct,
- 20. The diagnostic kit of claim 18 wherein said antibody is a monoclonal antibody.
- 21. The diagnostic kit of claim 19 further comprising a synthetic peptide or a synthetic protein conjugated to CEP.
- 22. The diagnostic kit of claim 21 further comprising a synthetic peptide or a synthetic protein conjugated to a 2-(ω-carboxyalkyl) pyrrole (CAP) other than CEP.
- 23. A CEP adduct comprising CEP conjugated to a carrier with a primary amino group.
- 24. The CEP adducts of claim 23, wherein the carrier is a peptide or protein.
Parent Case Info
[0001] This application which claims priority from U.S. Provisional Application Ser. No. 60/287,543, filed on Apr. 30, 2001. This work was supported, at least in part, by grants GM21249 and HL53315 from the National Institutes of Health. The government has certain rights in this invention.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60287543 |
Apr 2001 |
US |